Valbiotis announces that it has received Food and Drug Administration (FDA) approval for New Dietary Ingredient (NDI) status
La Rochelle, December 11, 2023 (08:00 p.m. CEST) – Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a commercially-oriented company specializing in dietary supplements, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces that it has received approval from the Food and Drug Administration (FDA) for New Dietary Ingredient (NDI) status for a plant extract present in all its TOTUM products.
- La Rochelle, December 11, 2023 (08:00 p.m. CEST) – Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a commercially-oriented company specializing in dietary supplements, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces that it has received approval from the Food and Drug Administration (FDA) for New Dietary Ingredient (NDI) status for a plant extract present in all its TOTUM products.
- The US Food and Drug Administration (FDA) imposes specific requirements on manufacturers and distributors wishing to market dietary supplements containing "new dietary ingredients".
- Sébastien PELTIER, CEO and co-founder, emphasizes: "Obtaining the New Dietary Ingredient (NDI) status for this plant extract is a gratifying milestone, albeit expected, marking the conclusion of a standard authorization process.
- This comes at a time when the growing incidence of metabolic and cardiovascular diseases worldwide poses a public health challenge."